Go Pro
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel Free BLRX Stock Alerts

BioLineRx (BLRX) Financials

BioLineRx logo
$2.84 +0.02 (+0.53%)
Closing price 03:59 PM Eastern
Extended Trading
$2.84 0.00 (0.00%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for BioLineRx

Annual Income Statements for BioLineRx

This table shows BioLineRx's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -14 -16 -24 -23 -25 -30 -27 -25 -50 -8.21 -2.03
Consolidated Net Income / (Loss)		 -14 -16 -24 -23 -25 -30 -27 -25 -61 -9.22 -2.03
Net Income / (Loss) Continuing Operations		 -16 -16 -24 -25 -30 -24 -25 -31 -50 -27 -10
Total Pre-Tax Income 		-16 -17 -25 -26 -30 -25 -26 -31 -52 -29 -12
Total Operating Income		 -16 -17 -25 -26 -28 -23 -25 -29 -50 -20 -10
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.11 20 0.95
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4.80 29 1.18
Operating Revenue		 - - - - - - 0.00 0.00 4.80 29 1.18
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.69 9.26 0.23
Operating Cost of Revenue		 - - - - - - 0.00 0.00 3.69 9.26 0.23
Total Operating Expenses		 16 17 25 26 28 23 25 29 51 39 11
Selling, General & Admin Expense		 3.70 3.98 4.04 4.44 3.82 3.91 4.31 5.07 6.31 6.32 3.14
Marketing Expense		 1.00 1.35 1.69 1.36 0.86 0.84 1.00 6.46 25 24 0.00
Research & Development Expense		 11 11 20 20 23 18 19 18 13 9.15 8.09
Total Other Income / (Expense), net		 -0.11 -0.02 -0.02 -0.47 -2.28 -1.63 -1.01 -2.16 -2.17 -9.12 -1.28
Interest Expense		 0.11 0.02 0.02 0.47 2.28 1.63 1.01 2.16 2.17 9.12 1.28
Income Tax Expense		 -0.46 -0.48 -1.17 -0.72 -0.78 -0.24 -0.56 -0.69 -2.07 -1.87 -1.46
Other Adjustments to Consolidated Net Income / (Loss)		 1.45 0.21 -0.26 2.40 4.17 -5.70 -1.83 5.67 - 18 8.08
Basic Earnings per Share		 ($0.28) ($0.28) ($0.27) ($0.21) ($0.17) ($0.12) ($0.04) ($0.03) - ($0.01) $0.00
Weighted Average Basic Shares Outstanding		 51.41M 56.14M 89.97M 108.60M 146.41M 252.84M 662.93M 773.96M 963.37M 1.20B 2.47B
Diluted Earnings per Share		 ($0.28) ($0.28) ($0.27) ($0.21) ($0.17) ($0.12) ($0.04) ($0.03) - ($0.01) $0.00
Weighted Average Diluted Shares Outstanding		 - - 105.06M 114.93M 171.27M 252.84M 715.16M 922.96M 963.37M 1.20B 2.61B
Basic & Diluted Earnings per Share		 ($0.28) ($0.28) ($0.27) ($0.21) ($0.17) ($0.12) ($0.04) ($0.03) - ($0.01) $0.00
Weighted Average Basic & Diluted Shares Outstanding		 - - 105.06M 114.93M 171.27M 252.84M 715.16M 922.96M 963.37M 1.20B 2.61B

Quarterly Income Statements for BioLineRx

No quarterly income statements for BioLineRx are available.

Annual Cash Flow Statements for BioLineRx

This table details how cash moves in and out of BioLineRx's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -29 -5.26 -36 -5.54 -66 -58 -94 -64 -89 -54 -49
Net Cash From Operating Activities		 -77 -47 -69 -59 -66 -54 -90 -70 -87 -59 -44
Net Cash From Continuing Operating Activities		 -77 -47 -69 -59 -66 -54 -90 -70 -87 -59 -44
Net Income / (Loss) Continuing Operations		 -14 -16 -24 -23 -25 -30 -27 -25 -61 -9.22 -2.03
Consolidated Net Income / (Loss)		 -14 -16 -24 -23 -25 -30 -27 -25 -61 -9.22 -2.03
Depreciation Expense		 0.44 0.48 0.48 0.55 0.94 0.93 0.70 0.65 1.38 4.07 0.52
Non-Cash Adjustments To Reconcile Net Income		 -63 -32 -48 -36 -44 -24 -63 -48 -31 -45 -43
Changes in Operating Assets and Liabilities, net		 0.20 0.37 3.06 -0.77 3.22 -1.72 -0.56 1.89 3.20 -8.82 -0.05
Net Cash From Investing Activities		 47 42 33 45 -0.07 0.00 -0.10 -0.13 -0.12 -0.05 -0.03
Net Cash From Continuing Investing Activities		 47 42 33 45 -0.07 0.00 -0.10 -0.13 -0.12 -0.05 -0.03
Purchase of Property, Plant & Equipment		 -2.68 -0.05 - -0.17 -0.07 0.00 -0.10 -0.13 -0.12 -0.05 -0.03
Net Cash From Financing Activities		 0.44 -0.09 -0.09 9.22 -0.89 -3.13 -3.37 6.30 -1.52 4.81 -4.50
Net Cash From Continuing Financing Activities		 0.44 -0.09 -0.09 9.22 -0.89 -3.13 -3.37 6.30 -1.52 4.81 -4.50
Repayment of Debt		 -0.03 -0.09 0.00 0.00 -0.89 -3.13 -3.38 -2.83 -1.54 -14 -4.50
Issuance of Debt		 0.47 0.00 -0.09 9.22 - 0.00 0.00 9.13 0.00 19 0.00
Other Financing Activities, net		 - - - - 0.00 0.01 0.01 0.01 0.03 0.02 0.00
Cash Interest Paid		 0.17 0.45 0.49 0.83 0.87 0.38 0.14 0.34 2.02 1.99 1.15

Quarterly Cash Flow Statements for BioLineRx

No quarterly cash flow statements for BioLineRx are available.

Annual Balance Sheets for BioLineRx

This table presents BioLineRx's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 39 61 56 54 47 81 76 64 39 41
Total Current Assets		 36 50 32 28 23 57 52 47 27 24
Cash & Equivalents		 2.47 5.11 3.40 5.30 17 13 11 4.26 10 3.25
Short-Term Investments		 33 44 27 22 5.76 44 40 39 9.13 18
Accounts Receivable		 0.22 0.59 1.34 0.61 0.14 0.14 0.72 1.19 3.95 0.46
Inventories, net		 - - - - - - 0.00 1.95 3.15 2.15
Prepaid Expenses		 0.31 0.37 0.54 0.11 0.15 0.13 0.20 1.05 0.44 0.20
Plant, Property, & Equipment, net		 2.61 2.51 2.23 1.82 1.34 0.95 0.73 0.47 0.39 0.16
Plant, Property & Equipment, gross		 2.61 2.51 2.23 1.82 1.34 0.95 0.73 0.47 0.39 0.16
Total Noncurrent Assets		 0.18 8.02 22 24 23 23 24 16 11 17
Intangible Assets		 0.18 7.02 22 22 22 22 22 15 10 16
Other Noncurrent Operating Assets		 0.00 1.00 0.00 1.65 1.36 1.33 1.77 1.42 0.97 0.70
Total Liabilities & Shareholders' Equity		 39 61 56 54 47 81 76 64 39 41
Total Liabilities		 3.91 8.08 15 20 25 13 26 51 25 18
Total Current Liabilities		 3.66 6.72 6.75 12 11 9.72 11 43 15 12
Short-Term Debt		 0.09 0.09 0.90 2.69 3.09 2.76 1.54 3.15 4.48 4.48
Accounts Payable		 3.57 6.63 5.86 9.07 7.36 6.79 8.71 14 8.71 5.24
Other Current Liabilities		 - - - 0.20 0.19 0.17 0.43 13 0.52 0.23
Total Noncurrent Liabilities		 0.25 1.36 8.16 8.22 15 3.59 15 7.92 10 5.44
Long-Term Debt		 0.25 0.16 7.84 5.80 2.74 0.00 8.63 6.63 8.96 4.46
Capital Lease Obligations		 - - - 1.76 1.66 1.73 1.73 1.29 1.08 0.98
Total Equity & Noncontrolling Interests		 35 54 41 34 32 69 54 13 13 23
Total Preferred & Common Equity		 35 53 42 33 22 68 51 25 13 18
Preferred Stock		 200 241 250 266 279 339 339 355 354 328
Total Common Equity		 -165 -187 -209 -232 -247 -270 -285 -330 -339 -307
Common Stock		 1.51 2.84 3.11 4.69 9.87 21 27 31 38 73
Retained Earnings		 -175 -200 -223 -248 -278 -305 -330 -391 -400 -401
Accumulated Other Comprehensive Income / (Loss)		 -1.42 -1.42 -1.42 -1.42 -1.42 -1.42 -1.42 -1.42 -1.42 -1.42
Other Equity Adjustments		 11 12 12 13 23 15 19 30 25 22
Noncontrolling Interest		 - - - - - - - - 0.00 5.15

Quarterly Balance Sheets for BioLineRx

No quarterly balance sheets for BioLineRx are available.

Annual Metrics And Ratios for BioLineRx

This table displays calculated financial ratios and metrics derived from BioLineRx's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 0.00 105,063,437.00 114,933,144.00 171,269,528.00 349,169,545.00 715,156,008.00 922,958,942.00 2,173,178,330.00 2,173,178,330.00 2,232,601,990.00
DEI Adjusted Shares Outstanding		 0.00 0.00 175,106.00 191,555.00 4,281,738.00 8,729,239.00 17,878,900.00 23,073,974.00 54,329,458.00 54,329,458.00 2,232,601,990.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 -139.07 -119.87 -5.94 -3.44 -1.51 -1.08 -0.92 -0.15 0.00
Growth Metrics		 - - - - - - - - - - -
Profitability Metrics		 - - - - - - - - - - -
Net Operating Profit after Tax (NOPAT)		 -11 -12 -18 -18 -20 -16 -17 -20 -35 -14 -7.20
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -31.00% -143.23% -51.06% -21.65%
Earnings before Interest and Taxes (EBIT)		 -16 -17 -25 -26 -28 -23 -25 -29 -50 -20 -10
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -16 -16 -25 -25 -27 -22 -24 -29 -48 -16 -9.76
Valuation Ratios		 - - - - - - - - - - -
Leverage & Solvency		 - - - - - - - - - - -
Liquidity Ratios		 - - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -11 -23 -33 -16 -16 -17 -19 -13 -31 -12
Efficiency Ratios		 - - - - - - - - - - -
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 0.00 -0.25 4.85 20 17 17 16 15 -6.78 10 15
Increase / (Decrease) in Invested Capital		 0.00 -0.25 5.11 15 -3.42 0.35 -0.84 -1.56 -22 17 4.45
Book Value per Share		 $0.00 ($2.93) ($2.07) ($1.99) ($2.02) ($1.44) ($0.77) ($0.40) ($0.36) ($0.31) ($0.14)
Tangible Book Value per Share		 $0.00 ($2.93) ($2.15) ($2.19) ($2.21) ($1.57) ($0.84) ($0.43) ($0.37) ($0.32) ($0.14)
Total Capital		 0.00 35 54 50 44 40 73 66 24 28 33
Total Debt		 0.00 0.34 0.25 8.73 10 7.49 4.48 12 11 15 9.92
Total Long-Term Debt		 0.00 0.25 0.16 7.84 7.56 4.40 1.73 10 7.92 10 5.44
Net Debt		 0.00 -35 -49 -21 -17 -15 -53 -39 -32 -5.04 -11
Capital Expenditures (CapEx)		 2.68 0.05 0.34 0.17 0.07 0.00 0.10 0.13 0.12 0.05 0.03
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -3.09 -5.74 -4.03 -8.56 -7.26 -6.69 -8.22 -35 -3.39 -4.84
Debt-free Net Working Capital (DFNWC)		 0.00 33 44 26 19 15 50 43 7.54 16 16
Net Working Capital (NWC)		 0.00 32 44 25 16 12 48 41 4.40 12 12
Net Nonoperating Expense (NNE)		 3.06 4.28 6.68 5.04 5.77 14 9.71 4.54 26 -5.06 -5.17
Net Nonoperating Obligations (NNO)		 0.00 -35 -49 -21 -17 -15 -53 -39 -20 -3.35 -8.79
Total Depreciation and Amortization (D&A)		 0.44 0.48 0.48 0.55 0.94 0.93 0.70 0.65 1.38 4.07 0.52
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 ($4.05) ($3.15) ($0.17) ($0.12) ($0.04) ($1.20) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 6.00M 7.24M 146.41M 252.84M 662.93M 19.35M 0.00 2.23B 2.47B
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($4.05) ($3.15) ($0.17) ($0.12) ($0.04) ($1.20) $0.00 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 7.00M 7.66M 171.27M 349.17M 715.16M 23.07M 0.00 2.23B 2.61B
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 ($4.05) ($3.15) ($0.17) ($0.12) ($0.04) ($1.20) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 7.00M 7.66M 171.27M 349.17M 715.16M 23.07M 0.00 1.20B 2.61B
Normalized Net Operating Profit after Tax (NOPAT)		 -11 -12 -18 -18 -20 -16 -17 -20 -30 -14 -7.20
Debt Service Ratios		 - - - - - - - - - - -
Payout Ratios		 - - - - - - - - - - -

Quarterly Metrics And Ratios for BioLineRx

No quarterly metrics and ratios for BioLineRx are available.


Financials Breakdown Chart

BioLineRx Financials - Frequently Asked Questions

According to the most recent income statement we have on file, BioLineRx's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Over the last 10 years, BioLineRx's net income changed from -$14.40 million in 2015 to -$2.03 million in 2025, a change of -85.9%. Find out what analysts predict for BioLineRx in the coming months.

BioLineRx's total operating income in 2025 was -$10.29 million, based on the following breakdown:
  • Total Gross Profit: $950 thousand
  • Total Operating Expenses: $11.24 million

Over the last 10 years, BioLineRx's total revenue changed from $0.00 in 2015 to $1.18 million in 2025, a change of 118,000,000.0%.

BioLineRx's total liabilities were at $17.56 million at the end of 2025, a 31.0% decrease from 2024, and a 348.9% increase since 2016.

In the past 9 years, BioLineRx's cash and equivalents has ranged from $2.47 million in 2016 to $16.83 million in 2020, and is currently $3.25 million as of their latest financial filing in 2025.

Over the last 10 years, BioLineRx's book value per share changed from 0.00 in 2015 to -0.14 in 2025, a change of -13.8%.


Related Companies

Financial statements for NASDAQ:BLRX last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
BofA: Digital Dollar Coming 2025-2030
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel
Three oil giants buried the same discovery for 50 years
In 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the ...
Behind the Markets | Sponsoredtc pixel